AU2001262221A1 - Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use - Google Patents
Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical useInfo
- Publication number
- AU2001262221A1 AU2001262221A1 AU2001262221A AU6222101A AU2001262221A1 AU 2001262221 A1 AU2001262221 A1 AU 2001262221A1 AU 2001262221 A AU2001262221 A AU 2001262221A AU 6222101 A AU6222101 A AU 6222101A AU 2001262221 A1 AU2001262221 A1 AU 2001262221A1
- Authority
- AU
- Australia
- Prior art keywords
- preparation
- pharmaceutical use
- epothilone derivatives
- novel epothilone
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10020517A DE10020517A1 (en) | 2000-04-19 | 2000-04-19 | New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease |
DE10020517 | 2000-04-19 | ||
PCT/EP2001/004552 WO2001081342A2 (en) | 2000-04-19 | 2001-04-19 | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001262221A1 true AU2001262221A1 (en) | 2001-11-07 |
Family
ID=7640033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001262221A Abandoned AU2001262221A1 (en) | 2000-04-19 | 2001-04-19 | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040058969A1 (en) |
EP (1) | EP1276740A2 (en) |
JP (1) | JP2003531207A (en) |
AU (1) | AU2001262221A1 (en) |
DE (1) | DE10020517A1 (en) |
NO (1) | NO20025029D0 (en) |
WO (1) | WO2001081342A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69734362T2 (en) * | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | SYNTHESIS OF EPOTHILONES, INTERMEDIATE PRODUCTS, ANALOGUES AND USES THEREOF |
IL144519A0 (en) * | 1999-02-18 | 2002-05-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
WO2003077903A1 (en) * | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
DE60333754D1 (en) * | 2002-06-10 | 2010-09-23 | Novartis Ag | EPOTHILONE CONTAINING COMBINATIONS AND THEIR PHARMACEUTICAL USES |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DK1767535T3 (en) | 2002-08-23 | 2010-04-12 | Sloan Kettering Inst Cancer | Synthesis of epothilones, their intermediates, analogs and their use |
AU2003277298A1 (en) * | 2002-10-04 | 2004-05-04 | Pharmacia Corporation | Pharmaceutical compositions for treatment of parkinson's disease |
WO2006017761A2 (en) * | 2004-08-05 | 2006-02-16 | Emory University | Epothilone analogues as therapeutic agents |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
DE102007059752A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Functionalized solid polymer nanoparticles containing epothilones |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014202775A1 (en) | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT873341E (en) * | 1995-11-17 | 2004-02-27 | Biotechnolog Forschung Mbh Gbf | EPOTILONE DERIVATIVES PREPARATION AND UTILIZATION |
-
2000
- 2000-04-19 DE DE10020517A patent/DE10020517A1/en not_active Withdrawn
-
2001
- 2001-04-19 AU AU2001262221A patent/AU2001262221A1/en not_active Abandoned
- 2001-04-19 EP EP01936262A patent/EP1276740A2/en not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004552 patent/WO2001081342A2/en not_active Application Discontinuation
- 2001-04-19 US US10/257,925 patent/US20040058969A1/en not_active Abandoned
- 2001-04-19 JP JP2001578432A patent/JP2003531207A/en active Pending
-
2002
- 2002-10-18 NO NO20025029A patent/NO20025029D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2003531207A (en) | 2003-10-21 |
NO20025029L (en) | 2002-10-18 |
US20040058969A1 (en) | 2004-03-25 |
DE10020517A1 (en) | 2001-10-25 |
EP1276740A2 (en) | 2003-01-22 |
NO20025029D0 (en) | 2002-10-18 |
WO2001081342A3 (en) | 2002-05-10 |
WO2001081342A2 (en) | 2001-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001262221A1 (en) | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use | |
IL144501A0 (en) | Epothilone derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same | |
AU2001266583A1 (en) | Epothilone derivatives and methods for making and using the same | |
AU2001241068A1 (en) | Indole derivatives, process for preparation of the same and use thereof | |
AU2002338336A1 (en) | Epothilone derivatives and methods for making and using the same | |
AU2003233010A1 (en) | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof | |
AU2001241056A1 (en) | Spiro compounds, process for preparing the same and use thereof as drugs | |
HUP0302295A3 (en) | Thienodibenzoazulene derivatives, process for their preparation and use thereof | |
EE200100422A (en) | Epothilone derivatives, process for their preparation and pharmaceutical use | |
AU3156600A (en) | Novel epothilon derivatives, method for the production thereof and their pharmaceutical application | |
AU2001292331A2 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
AU2001292331A1 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
AU2000254308A1 (en) | Pyrazolopyrimidinone derivatives, process for their preparation and their use | |
AU7446900A (en) | Thioalkylamine derivatives and process for the preparation thereof | |
AU5368699A (en) | Derivatives of triptolide, and preparation and uses thereof | |
IL154986A0 (en) | Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
AU2001254812A1 (en) | 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations | |
AU2001252671A1 (en) | Pyridobenzodiazine derivatives and processes for the preparation thereof | |
AU2002227966A1 (en) | Coniosetin and derivatives thereof, method for producing the same and use thereof | |
AU2001284084A1 (en) | Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof | |
AU2003267848A1 (en) | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | |
AU5524400A (en) | Novel 6-amino-uracil derivatives, preparation and use thereof | |
AU2001260083A1 (en) | New pharmaceutical composition and the process for its preparation | |
AU2001237518A1 (en) | Polyfluoroalkylimidazole derivatives, their preparation and therapeutic application | |
AU2002227952A1 (en) | Klainetin and derivatives thereof, method for their production and the use of the same |